Uso de inhibidores de puntos de chequeo antes o después de trasplante alógeno de progenitores hematopoyéticos. Eficacia, seguridad y recomendaciones.

  • Gustavo Jarchum
Palabras clave: ipilimumab Nivolumab Pembrolizumab Transplante alogenico Enfermedad injerto contra huésped Linfoma

Resumen

Los IPC  son anticuerpos monoclonales que inhiben las vías de CTLA-4 y PD-1/PD-L1. Los anticuerpos que inhiben PD-1 de la interaccion con sus ligandos PDL1/2 son pembrolizumab(@Keytruda)y nivolumab (@Opdivo), estos tienen aprobación  por FDA y ANMAT.

Nivolumab para su uso en linfoma de Hodgkin Clasico  que han presentado recidiva o progresión post Transplante autologo de progenitores hematopoyéticos y tratamiento con Brentuximab vedotin (Anmat Disposicion 1804, 2017). (17)

Pembrolizumab, para adultos y pediátricos con linfoma de Hodgkin clásico refractario o  que hayan recaido a tres o mas líneas de tratamiento previas. Tambien aprobado para pacientes con Linfoma a Celulas Grandes B  Primario Mediastinal refractario o que haya recaido después de dos o mas líneas de tratamiento (Anmat Disposicion 1785,2018). (18) (19)

Ipilimumab(@Yervoy) es un monoclonal que inhibe la interaccion CTLA-4 / B27-B8; no esta aprobado su uso para enfermedades hematológicas.

Referencias bibliográficas

1. PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Haverkos B, Abbott D, et al. 2, 2017, Blood, Vol. 130, págs. 221-228.
2. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas. Goodman A, Patel S, Kurzrock R. 2016, Nature Reviews Clinical Oncology, págs. 1-18.
3. Profiling the immune checkpoint pathway in acute myeloid leukemia. Dama P, Tang M, Fulton N, et al . 2018, Journal of Clinical Oncology, págs. 7015-7015.
4. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity. Williams P, Basu S, Garcia-Manero G et al. s.l. : ASH 2017, 2017, Blood, pág. 1085.
5. Programmed Death 1 Expression on CD4+ T Cells Predicts Mortality after Allogeneic Stem Cell Transplantation . Schade H, Sen S, et al. 2016, BBMT, Vol. 22, págs. 2172-2179.
7. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Daver N, Basu S, Garcia-Manero G, et al. 15 suppl, 2017, Journal of Clinical Oncology , Vol. 35, págs. 7026-7026.
8. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. Davids M, Haesook K, Bachirereddy P, et al. 2016, NEJM, Vol. 375, págs. 143-153.
9. Significant risk of graft vs host diseasewith exposure to checkpoint inhibitors before and after allogeneic transplantation. Ijaz A, Khan A, Malik S, et al. 2019, Biology of Blood and Bone Marrow Transplantation , Vol. 25, págs. 94-99.
11. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Merryman R, Haesook K, Zinzani P, et al. 2017, BLOOD, Vol. 129, págs. 1380-1388.
12. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Schoch L, Cooke K, et al. 2018, Blood Advances, Vol. 2, págs. 2226-2229.
13. Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate. Santoro A, Castagna l, Magagnoli M, et al. 2185, s.l. : ASH 2018, 2018, Blood.
14. Post Allogeneic Stem Cell Transplant Cyclophosphamide improves Progresion Free Survivalin Pts with AML/MDS treated with CTLA-4 or PD-1 Blockade Prior to SCT. Oran B, Garcia-Manero G, Saliba R, et al. 132, 2018, Blood , pág. 483. ASH Meeting 2018.
15. Expression of PD-L1,PD-L2,PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. ;28(6):1280-1288. . Yang H, Bueso-Ramos C, Dinardo C et al. 6, 2014, Leukemia, Vol. 28, págs. 1280-1288.
16. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogenic transplantation for relapsed Hodgkin lymphoma. 2017. págs. 2471-2478. Vol. 130.
17. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Younes A, Santoro A et al. 2016, Lancet Oncol, Vol. 17, págs. 1283-1294.
18. Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Armand P, Rodig S, et al. s.l. : abs, 2018, Blood, pág. 228.
19. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. 2017, J Clinical Oncology, Vol. 35, págs. 2125-2132.
20. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Brahmer J, Lacchetti C, Schneider J, et al. 2018, Journa of Clinical Oncology, Vol. 36, págs. 1714-1768.
Publicado
2019-05-07
Sección
Nuevas Drogas